Related Experiment Videos

Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada

D A Kertesz1, M B Coulthart, J A Ryan

  • 1Bureau of Infectious Diseases, Laboratory Centre for Disease Control, Health Canada, Ottawa.

Insights

A new strain of serogroup B meningococcal disease (ET15) emerged in Canada following immunization campaigns for serogroup C. This variant may pose a significant public health risk due to its epidemic potential.

Area of Science:

  • Microbiology
  • Epidemiology
  • Public Health

Background:

  • Invasive meningococcal disease (IMD) is a significant public health concern in Canada.
  • Serogroup C meningococcal disease, specifically electrophoretic type 15 (ET15), has been the predominant genotype causing epidemics.
  • Mass immunization campaigns targeting serogroup C IMD were implemented across Canada.

Observation:

  • Between August 1993 and September 1995, nine cases of invasive meningococcal disease were identified.
  • These cases were caused by a variant of the ET15 genotype expressing serogroup B capsular polysaccharide.
  • The emergence of serogroup B:ET15 coincided temporally and geographically with serogroup C immunization efforts.

Findings:

  • A novel serogroup B meningococcal strain (ET15) emerged during a period of widespread vaccination against serogroup C.
  • The temporal and geographic association suggests a potential link between the immunization campaigns and the emergence of the serogroup B variant.
  • This serogroup B:ET15 strain may possess similar epidemic potential to its serogroup C predecessor.

Implications:

  • The emergence of serogroup B:ET15 highlights the adaptability of Neisseria meningitidis strains in response to public health interventions.
  • The lack of a vaccine for serogroup B meningococcal disease necessitates urgent public health surveillance and response strategies.
  • Understanding the dynamics of strain replacement is crucial for effective long-term control of invasive meningococcal disease.

Related Concept Videos